cyslt1 antagonists effective subset patients asthma good way predict given patients response examined interaction clinical response cyslt1 antagonist pranlukast dna sequence variant leukotriene c4 synthase ltc4 s gene japanese patients moderate asthma frequency ltc4 s allele NUMBER japanese general population n NUMBER NUMBER asthmatic subjects n NUMBER prospective open trial pranlukast NUMBER mg twice daily performed NUMBER patients moderate asthma controlled inhaled corticosteroid beclomethasone fluticasone allele carriers n NUMBER responded better pranlukast compared allele homozygotes n NUMBER NUMBER NUMBER vs NUMBER NUMBER improvement forced expiratory volume second fev1 NUMBER ltc4 s response inhaled salbutamol NUMBER microg observed NUMBER NUMBER vs NUMBER NUMBER improvement fev1 univariate analysis demonstrated better response pranlukast NUMBER improvement fev1 correlated ltc4 s genotype p NUMBER pretreatment airway reversibility salbutamol p NUMBER sex age atopic status urinary leukotriene e4 excretion rate daily dose inhaled corticosteroid furthermore multivariate regression analysis suggested ltc4 s genotype bronchodilatory effect salbutamol independent variables predict clinical response pranlukast p NUMBER conclude ltc4 s genotype predictive clinical response cyslt1 antagonist pranlukast japanese patients moderate asthma 444c c NUMBER NUMBER week NUMBER NUMBER NUMBER NUMBER c NUMBER NUMBER genotype stratified beta agonist microg day microg day